Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype

World Journal of Gastroenterology

Volumn 20, Issue 21, 2014, Pages 6400-6411

  Sugimoto, Mitsushige ^a   Furuta, Takahisa ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clarithromycin; Cytochrome P4502C19; Helicobacter pylori; Proton pomp inhibitor; Tailored eradication therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; ESOMEPRAZOLE; INTERLEUKIN 1BETA; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; ANTIINFECTIVE AGENT; CYP2C19 PROTEIN, HUMAN; PROTON PUMP INHIBITOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CLEARANCE; DRUG EFFICACY; ENZYME POLYMORPHISM; ERADICATION THERAPY; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; META ANALYSIS (TOPIC); PHARMACODYNAMICS; STOMACH ACID SECRETION; CLINICAL TRIAL (TOPIC); GENETIC POLYMORPHISM; GENETICS; HELICOBACTER INFECTIONS; MICROBIAL SENSITIVITY TEST; PREVALENCE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP2C19; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMORPHISM, GENETIC; PREVALENCE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84902074192     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i21.6400     Document Type: Article

References (86)

1. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
2. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789 [PMID: 11556297 DOI: 10.1056/NEJMoa001999]
3. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-194 [PMID: 14722144 DOI: 10.1001/jama.291.2.187]
4. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, Shiratori Y. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005; 100: 1037-1042 [PMID: 15842576 DOI: 10.1111/j.1572-0241.2005.41384.x]
5. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-1252 [PMID: 8613015 DOI: 10.1053/gast.1996.v110. pm8613015]
6. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 639-642 [PMID: 9264278]
7. Wotherspoon AC, Doglioni C, de Boni M, Spencer J, Isaacson PG. Antibiotic treatment for low-grade gastric MALT lymphoma. Lancet 1994; 343: 1503 [PMID: 7911202 DOI: 10.1016/S0140-6736(94)92613-1]
8. Sugimoto M, Kajimura M, Shirai N, Furuta T, Kanaoka S, Ikuma M, Sato Y, Hishida A. Outcome of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy. Intern Med 2006; 45: 405-409 [PMID: 16617193 DOI: 10.2169/internalmedicine. 45.1473]
9. Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998; 352: 878 [PMID: 9742983 DOI: 10.1016/S0140-6736(05)60004-9]
10. Tebbe B, Geilen CC, Schulzke JD, Bojarski C, Radenhausen M, Orfanos CE. Helicobacter pylori infection and chronic urticaria. J Am Acad Dermatol 1996; 34: 685-686 [PMID: 8601663 DOI: 10.1016/S0190-9622(96)80086-7]
11. Annibale B, Marignani M, Monarca B, Antonelli G, Marcheggiano A, Martino G, Mandelli F, Caprilli R, Delle Fave G. Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med 1999; 131: 668-672 [PMID: 10577329 DOI: 10.7326/0003-4819-131-9-199911020-00006]
12. Asaka M, Sugiyama T, Kato M, Satoh K, Kuwayama H, Fukuda Y, Fujioka T, Takemoto T, Kimura K, Shimoyama T, Shimizu K, Kobayashi S. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 2001; 6: 254-261 [PMID: 11683930 DOI: 10.1046/j.1523-5378.2001.00037.x]
13. Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J, Sato S, Abe H, Arita T. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002; 16: 1933-1938 [PMID: 12390102 DOI: 10.1046/j.1365-2036.2002.01368.x]
14. Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, Armuzzi A, Zocco MA, Santarelli L, Arancio F, Gasbarrini G. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 1339-1343 [PMID: 11012480 DOI: 10.1046/j.1365-2036.2000.00846.x]
15. Sharara AI, Chaar HF, Aoun E, Abdul-Baki H, Araj GF, Kanj SS. Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. Helicobacter 2006; 11: 231-236 [PMID: 16882325 DOI: 10.1111/j.1523-5378.2006.00416.x]
16. Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for secondline Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 2003; 17: 119-123 [PMID: 12492740 DOI: 10.1046/j.1365-2036.2003.01401.x]
17. Kawakami E, Machado RS, Ogata SK, Langner M, Fukushima E, Carelli AP, Bonucci VC, Patricio FR. Furazolidonebased triple therapy for H pylori gastritis in children. World J Gastroenterol 2006; 12: 5544-5549 [PMID: 17006997]
18. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69: 158-168 [PMID: 11240980 DOI: 10.1067/mcp.2001.113959]
19. Sugimoto M, Yamaoka Y. Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy. Arch Immunol Ther Exp (Warsz) 2009; 57: 45-56 [PMID: 19219527 DOI: 10.1007/s00005-009-0007-z]
20. Furuta T, Soya Y, Sugimoto M, Nishino M, Yamade M, Uotani T, Kodaira C, Sahara S, Ichikawa H, Yamada T, Osawa S, Sugimoto K, Maekawa M, Watanabe H, Umemura K. Rapid automated genotyping of CYP2C19 and Helicobacter pylori 23S rRNA gene in gastric juice. J Gastroenterol Hepatol Res 2013; 2: 506-512
21. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8: 888-889 [PMID: 2512133 DOI: 10.1007/BF01963775]
22. Hunt RH. pH and Hp-gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol 1993; 88: 481-483 [PMID: 8470623]
23. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004; 76: 290-301 [PMID: 15470328 DOI: 10.1016/j.clpt.2004.06.008]
24. Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Hishida A, Ohashi K, Ishizaki T. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin Pharmacol Ther 2005; 77: 302-311 [PMID: 15903128 DOI: 10.1016/j.clpt.2004.10.010]
25. Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Yamade M, Sahara S, Ichikawa H, Sugimoto K, Miyajima H, Furuta T. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther 2012; 36: 627-634 [PMID: 22882464 DOI: 10.1111/apt.12014]
26. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929-1937 [PMID: 11736724 DOI: 10.1046/j.1365-2036.2001.01108.x]
27. Shirai N, Furuta T, Xiao F, Kajimura M, Hanai H, Ohashi K, Ishizaki T. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther 2002; 16: 837-846 [PMID: 11929404 DOI: 10.1046/j.1365-2036.2002.01229.x]
28. Kodaira C, Sugimoto M, Nishino M, Yamade M, Shirai N, Uchida S, Ikuma M, Yamada S, Watanabe H, Hishida A, Furuta T. Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. Eur J Clin Pharmacol 2009; 65: 593-600 [PMID: 19238367 DOI: 10.1007/s00228-009-0625-8]
29. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65: 552-561 [PMID: 10340921]
30. Furuta T, Sugimoto M, Shirai N, Matsushita F, Nakajima H, Kumagai J, Senoo K, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Umemura K, Ishizaki T, Hishida A. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment Pharmacol Ther 2007; 26: 693-703 [PMID: 17697203 DOI: 10.1111/j.1365-2036.2007.03408.x]
31. Wolfe MM, Nompleggi DJ. Cytokine inhibition of gastric acid secretion--a little goes a long way. Gastroenterology 1992; 102: 2177-2178 [PMID: 1587446]
32. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, Rabkin CS. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402 [PMID: 10746728 DOI: 10.1038/35006081]
33. Furuta T, Sagehashi Y, Shirai N, Sugimoto M, Nakamura A, Kodaira M, Kenmotsu K, Nagano M, Egashira T, Ueda K, Yoneyama M, Ohashi K, Ishizaki T, Hishida A. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol 2005; 3: 564-573 [PMID: 15952098 DOI: 10.1016/S1542-3565(04)00779-7]
34. Sugimoto M, Furuta T, Shirai N, Ikuma M, Hishida A, Ishizaki T. Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin- sensitive strains of Helicobacter pylori by triple therapy. Clin Pharmacol Ther 2006; 80: 41-50 [PMID: 16815316 DOI: 10.1016/j.clpt.2006.03.007]
35. Sugimoto M, Furuta T, Yamaoka Y. Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori. J Gastroenterol Hepatol 2009; 24: 1725-1732 [PMID: 20136959 DOI: 10.1111/j.1440-1746.2009.06047.x]
36. Lu H, Hsu PI, Graham DY, Yamaoka Y. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 2005; 128: 833-848 [PMID: 15825067 DOI: 10.1053/j.gastro.2005.01.009]
37. Shiota S, Nguyen LT, Murakami K, Kuroda A, Mizukami K, Okimoto T, Kodama M, Fujioka T, Yamaoka Y. Association of helicobacter pylori dupA with the failure of primary eradication. J Clin Gastroenterol 2012; 46: 297-301 [PMID: 22298090 DOI: 10.1097/MCG.0b013e318243201c]
38. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. Am J Gastroenterol 1998; 93: 386-389 [PMID: 9517645]
39. Ménard A, Santos A, Mégraud F, Oleastro M. PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. Antimicrob Agents Chemother 2002; 46: 1156-1157 [PMID: 11897613 DOI: 10.1128/AAC.46.4.1156-1157.2002]
40. Stone GG, Shortridge D, Versalovic J, Beyer J, Flamm RK, Graham DY, Ghoneim AT, Tanaka SK. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother 1997; 41: 712-714 [PMID: 9056021]
41. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343-357 [PMID: 17635369 DOI: 10.1111/j.1365-2036.2007.03386.x]
42. Megraud F. Helicobacter pylori and antibiotic resistance. Gut 2007; 56: 1502 [PMID: 17938430 DOI: 10.1136/gut.2007.132514]
43. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Nakagawa K, Sugimura H, Ohashi K, Ishizaki T. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001; 11: 341-348 [PMID: 11434512 DOI: 10.1097/00008571-200106000-00009]
44. Calvet X, García N, López T, Gisbert JP, Gené E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603-609 [PMID: 10792124 DOI: 10.1046/j.1365-2036.2000.00744.x]
45. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147: 553-562 [PMID: 17938394 DOI: 10.7326/0003-4819-147-8-200710160-00008]
46. Barer D, Ogilvie A, Henry D, Dronfield M, Coggon D, French S, Ellis S, Atkinson M, Langman M. Cimetidine and tranexamic acid in the treatment of acute upper-gastrointestinal- tract bleeding. N Engl J Med 1983; 308: 1571-1575 [PMID: 6343868 DOI: 10.1056/NEJM198306303082606]
47. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 1992; 51 Suppl 1: 59-67 [PMID: 1397746 DOI: 10.1159/000200917]
48. Sugimoto M, Nishino M, Kodaira C, Yamade M, Uotani T, Ikuma M, Furuta T. Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin. Digestion 2012; 85: 9-17 [PMID: 22122999 DOI: 10.1159/000329295]
49. Yang JC, Wang HL, Chern HD, Shun CT, Lin BR, Lin CJ, Wang TH. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazoleamoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy 2011; 31: 227-238 [PMID: 21361732 DOI: 10.1159/000331138]
50. Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Ikuma M, Ishizaki T, Hishida A. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007; 12: 317-323 [PMID: 17669104 DOI: 10.1111/j.1523-5378.2007.00508.x]
51. Labenz J, Stolte M, Blum AL, Jorias I, Leverkus F, Sollböhmer M, Bertrams J, Börsch G. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995; 37: 39-43 [PMID: 7672677 DOI: 10.1136/gut.37.1.39]
52. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut 1998; 43 Suppl 1: S56-S60 [PMID: 9764042 DOI: 10.1136/gut.43.2008.S56]
53. Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idström JP, Cederberg C, Spiller RC. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996; 111: 358-367 [PMID: 8690200 DOI: 10.1053/gast.1996.v111.pm8690200]
54. Marcus EA, Inatomi N, Nagami GT, Sachs G, Scott DR. The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. Aliment Pharmacol Ther 2012; 36: 972-979 [PMID: 23009227 DOI: 10.1111/apt.12059]
55. Heifets LB, Lindholm-Levy PJ, Comstock RD. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis 1992; 145: 856-858 [PMID: 1532486 DOI: 10.1164/ajrccm/145.4_Pt_1.856]
56. Hixson LJ, Kelley CL, Jones WN, Tuohy CD. Current trends in the pharmacotherapy for peptic ulcer disease. Arch Intern Med 1992; 152: 726-732 [PMID: 1558429 DOI: 10.1001/archint e.1992.00400160044009]
57. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol 1995; 35: 277-305 [PMID: 7598495 DOI: 10.1146/annurev.pa.35.040195.001425]
58. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-991 [PMID: 7666920 DOI: 10.1056/NEJM199510123331508]
59. Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T, Sato Y, Kajimura M, Futami H, Takayanagi S, Yamada M, Ohashi K, Ishizaki T, Hanai H. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72: 453-460 [PMID: 12386647 DOI: 10.1067/mcp.2002.127637]
60. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13 Suppl 3: 27-36 [PMID: 10491726 DOI: 10.1046/j.1365-2036.1999.00022.x]
61. Chang M, Dahl ML, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358-363 [PMID: 8747407 DOI: 10.1097/00008 571-199512000-00004]
62. Chang M, Tybring G, Dahl ML, Götharson E, Sagar M, Seensalu R, Bertilsson L. Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39: 511-518 [PMID: 7669487 DOI: 10.1111/j.1365-2125.1995. tb04488.x]
63. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60: 661-666 [PMID: 8988068 DOI: 10.1016/S0009-9236(96)90214-3]
64. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001; 70: 484-492 [PMID: 11719736 DOI: 10.1067/mcp.2001.119721]
65. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status. Clin Pharmacol Ther 1995; 58: 143-154 [PMID: 7648764 DOI: 10.1016/0009-9236(95)90192-2]
66. Abelö A, Andersson TB, Antonsson M, Naudot AK, Skånberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 966-972 [PMID: 10901708]
67. Hassan-Alin M, Andersson T, Niazi M, Röhss K. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol 2005; 60: 779-784 [PMID: 15578172 DOI: 10.1007/s00228-004-0841-1]
68. Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther 2013; 38: 1129-1137 [PMID: 24099474 DOI: 10.1111/apt.12492]
69. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103-113 [PMID: 16413245 DOI: 10.1016/j.clpt.2005.10.002]
70. Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Andersson T, Regårdh CG, Lou YC, Zhang Y. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994; 16: 214-215 [PMID: 8009572 DOI: 10.1097/00007691-199404000-00018]
71. de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58: 404-411 [PMID: 7586932 DOI: 10.1016/0009-9236(95)90053-5]
72. Shimatani T, Inoue M, Kuroiwa T, Horikawa Y. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 2004; 19: 113-122 [PMID: 14687173 DOI: 10.1046/j.1365-2036.2003.01821.x]
73. Lou HY, Chang CC, Sheu MT, Chen YC, Ho HO. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol 2009; 65: 55-64 [PMID: 18751689 DOI: 10.1007/s00228-008-0552-0]
74. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004; 76: 201-209 [PMID: 15371981 DOI: 10.1016/j.clpt.2004.05.002]
75. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One 2013; 8: e62162 [PMID: 23646118 DOI: 10.1371/journal.pone.0062162]
76. Kurzawski M, Gawrońska-Szklarz B, Wrześniewska J, Siuda A, Starzyńska T, Droździk M. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 2006; 62: 877-880 [PMID: 16912869 DOI: 10.1007/s00228-006-0183-2]
77. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006; 101: 1467-1475 [PMID: 16863547 DOI: 10.1111/j.1572-0241.2006.00717.x]
78. Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 2001; 15: 793-803 [PMID: 11380317 DOI: 10.1046/j.1365-2036.2001.00980.x]
79. Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, Ohashi K, Ishizaki T. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 2003; 50: 2274-2278 [PMID: 14696516]
80. Bayerdörffer E, Miehlke S, Mannes GA, Sommer A, Höchter W, Weingart J, Heldwein W, Klann H, Simon T, Schmitt W. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995; 108: 1412-1417 [PMID: 7729633 DOI: 10.1016/0016-5085(95)90689-4]
81. Shirai N, Sugimoto M, Kodaira C, Nishino M, Ikuma M, Kajimura M, Ohashi K, Ishizaki T, Hishida A, Furuta T. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol 2007; 63: 743-749 [PMID: 17565490 DOI: 10.1007/s00228-007-0302-8]
82. Isomoto H, Inoue K, Furusu H, Enjoji A, Fujimoto C, Yamakawa M, Hirakata Y, Omagari K, Mizuta Y, Murase K, Shimada S, Murata I, Kohno S. High-dose rabeprazoleamoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 18: 101-107 [PMID: 12848631 DOI: 10.1046/j.1365-2036.2003.01659.x]
83. Athamna A, Athamna M, Medlej B, Bast DJ, Rubinstein E. In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis. J Antimicrob Chemother 2004; 53: 609-615 [PMID: 14998982 DOI: 10.1093/jac/dkh130]
84. Miehlke S, Kirsch C, Schneider-Brachert W, Haferland C, Neumeyer M, Bästlein E, Papke J, Jacobs E, Vieth M, Stolte M, Lehn N, Bayerdörffer E. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003; 8: 310-319 [PMID: 12950604 DOI: 10.1046/j.1523-5378.2003.00158.x]
85. Kawai T, Yamagishi T, Yagi K, Kataoka M, Kawakami K, Sofuni A, Itoi T, Sakai Y, Moriyasu F, Osaka Y, Takagi Y, Aoki T, Rimbara E, Noguchi N, Sasatsu M. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol 2008; 23 Suppl 2: S171-S174 [PMID: 19120893 DOI: 10.1111/j.1440-1746.2008.05408.x]
86. Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, Iwaizumi M, Yamade M, Terakawa I, Ohashi K, Ishizaki T, Hishida A. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007; 81: 521-528 [PMID: 17215846 DOI: 10.1038/sj.clpt.6100043]